Trifluoroproscaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Trifluoroproscaline (TFP), also known as 4-(3,3,3-trifluoropropoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a trifluorinated derivative of proscaline.[1][2][3] Based on limited trials, trifluoroproscaline is active at a dose of 33 to 66 mg or more orally and its duration is unknown.[1][2][3] Initial trials provided evidence of effects including good fantasy and slight color intensification.[1] The drug might be less potent than proscaline similarly to fluoroproscaline.[2] It acts as a low-potency serotonin 5-HT2A receptor partial agonist and also interacts with other serotonin receptors and targets.[3] Trifluoroproscaline was first described in the scientific literature by Daniel Trachsel in 2012.[1][3][2] Its pharmacology was subsequently studied in greater detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[4]
- None
| |
| Clinical data | |
|---|---|
| Other names | TFP; 3,3,3-Trifluoroproscaline; 3,3,3-TFP; 4-(3,3,3-Trifluoropropoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(3,3,3-trifluoropropoxy)phenethylamine |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1][3] |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H18F3NO3 |
| Molar mass | 293.286 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
